This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
SNY Stock Down on Double Trouble With Multiple Sclerosis Drug
by Zacks Equity Research
Sanofi shares slide after the FDA again delays its review of its MS drug tolebrutinib, and a phase III study fails to hit its primary endpoint.
SNYNegative Net Change ANIPNegative Net Change CRMDPositive Net Change
biotechs medical pharmaceuticals
KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data
by Zacks Equity Research
Kyverna Therapeutics shares jump 23% after a registrational phase II study of miv-cel meets primary and all secondary efficacy goals for treating stiff person syndrome.
ANIPNegative Net Change CRMDPositive Net Change CSTLPositive Net Change KYTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike
by Zacks Equity Research
CHMP backs EU approval of Moderna's next-generation mNexspike COVID-19 vaccine, with a final European Commission decision expected shortly.
MRNANegative Net Change ANIPNegative Net Change CRMDPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals vaccines
Eli Lilly or Merck: Where Should Investors Put Their Money?
by Kinjel Shah
LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.
NVONegative Net Change MRKNegative Net Change LLYNegative Net Change CDTXNegative Net Change
pharmaceuticals
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
by Kinjel Shah
MindMed and four other biotech disruptors face pivotal studies and FDA decisions in 2026, setting up high-risk, high-reward opportunities for bold investors
CELCNegative Net Change OCGNPositive Net Change KROSPositive Net Change MNMDPositive Net Change KYTXNegative Net Change
pharmaceuticals
How AbbVie's Pipeline Is Lining Up Key Product Launches
by Sundeep Ganoria
ABBV is lining up multiple late-stage launches, from Rinvoq label expansions to Parkinson???s and oncology assets nearing FDA decisions.
JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal
by Zacks Equity Research
Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.
GSKNegative Net Change GILDNegative Net Change FOLDPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Top Research Reports for Microsoft, Novartis & RTX
by Mark Vickery
Microsoft, Novartis and RTX headline Zacks' top research picks, spotlighting cloud, pharma innovation and defense demand shaping market leaders.
RYAAYNegative Net Change NVSNegative Net Change MSFTPositive Net Change JCIPositive Net Change VLONegative Net Change AIRTPositive Net Change RTXNegative Net Change
aerospace computers pharmaceuticals transportation
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval
by Zacks Equity Research
NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger weight loss.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
RCUS Stock Down on Decision to Discontinue GILD Partnered Study
by Zacks Equity Research
Arcus halts the late-stage STAR-221 study for futility, dealing a setback to its domvanalimab program with Gilead. Stock down.
GILDNegative Net Change FOLDPositive Net Change CRMDPositive Net Change RCUSPositive Net Change
biotechnology biotechs medical pharmaceuticals
MRK Gets Positive CHMP Opinion for Expanded Use of Winrevair in PAH
by Zacks Equity Research
Merck secures a positive CHMP opinion to expand Winrevair's PAH use, potentially broadening treatment to adult patients across WHO FC II-IV.
JNJNegative Net Change MRKNegative Net Change UTHRNegative Net Change
pharmaceuticals
BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechs medical pharmaceuticals
Buy These 5 Best Value Stocks to Boost Your Portfolio in December
by Kinjel Shah
Here we discuss five value stocks that are cheap in terms of price-to-book, price-to-sales and PEG. These are StoneCo, GM, EnerSys, Deutsche Bank and Keros.
DBNegative Net Change GMNegative Net Change ENSNegative Net Change STNENegative Net Change KROSPositive Net Change
auto-tires-trucks computers finance pharmaceuticals
Take the Zacks Approach to Beat the Markets: Liquidia, Western Digital & Johnson & Johnson in Focus
by Santanu Roy
Liquidia shares have surged 43.9% since an October upgrade, as Zacks highlights stock wins and portfolio results despite a volatile market.
JNJNegative Net Change WDCPositive Net Change PEPNegative Net Change HIINegative Net Change CORNegative Net Change CMCNegative Net Change HCANegative Net Change FICONegative Net Change COHRNegative Net Change NOBLNegative Net Change NTBPositive Net Change LQDAPositive Net Change
aerospace business-services computers consumer-staples finance industrial-products medical pharmaceuticals tech-stocks
Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win
by Zacks Equity Research
LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.
PFENegative Net Change NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?
by Ahan Chakraborty
Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud growth and elevate execution risks.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?
by Zacks Equity Research
BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.
RHHBYNegative Net Change BMYNegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Kymera's Eczema Drug Gets Fast Track Designation in the United States
by Zacks Equity Research
KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.
SNYNegative Net Change GILDNegative Net Change KYMRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE?
by Kanishka Das
Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.
AZNNegative Net Change RHHBYNegative Net Change BMYNegative Net Change MRKNegative Net Change
pharmaceuticals
Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis
by Sundeep Ganoria
AMGN gains momentum as Uplizna wins FDA approval for generalized myasthenia gravis, adding a twice-yearly dosing option in a crowded autoimmune market.
JNJNegative Net Change AMGNPositive Net Change ARGXPositive Net Change
biotechs medical pharmaceuticals
AbbVie Slipped Below 50-Day SMA Last Week: How to Play the Stock
by Kinjel Shah
AbbVie dips below its 50-day SMA, but strong immunology momentum and a resilient long-term trend keep the story compelling.
AZNNegative Net Change JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
pharmaceuticals
Tracking the Top-Performing Russell 2000 Stocks Against the Zacks Rank
by Shaun Pruitt
Adding to the unusually strong performance of the Russell 2000 this year, these top performers may certainly serve as stocks to add to your watchlist
BETRNegative Net Change COGTNegative Net Change CELCNegative Net Change RGCNegative Net Change OPENPositive Net Change IWMNegative Net Change
artificial-intelligence biotechnology earnings finance inflation interest-rate investing medical oncology-screening pharmaceuticals real-estate
Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III
by Zacks Equity Research
RHHBY's giredestrant cuts the risk of invasive disease recurrence or death by 30% in phase III, fueling momentum for a next-generation endocrine therapy.
RHHBYNegative Net Change LLYNegative Net Change ANIPNegative Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?
by Ahan Chakraborty
LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in the development of their GLP-1 therapies.
NVONegative Net Change LLYNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
WVE Stock Surges More Than 180% in a Week: What Is Driving This Rally?
by Zacks Equity Research
Wave Life Sciences' shares jump 183% as early INLIGHT data on weight-loss drug WVE-007 show notable visceral fat cuts and gains in lean mass.
NVONegative Net Change LLYNegative Net Change WVEPositive Net Change
biotechs medical pharmaceuticals